CUMULATIVE INDEX 1994

Volume 23

March	MULTIPLE ENDOCRINE NEOPLASIA, pages 1–233
June	ENDOCRINE HYPERTENSION, pages 235–449
September	CUSHING'S SYNDROME, pages 451–697
December	CLINICAL ANDROLOGY, pages 699–957

Note: Page numbers of issues and article titles are in **boldface** type.

ACE. See *Angiotensin-converting enzyme (ACE) inhibitors.*
Acrosome reaction test, of sperm function, assessment in, 737–738
monitoring in, 736–737
stimulus selection in, 738
viability versus motility in, 738–739
ACTH. See *Adrenocorticotropin hormone (ACTH).*
Adenoma, adrenal, Cushing's syndrome from, 301
treatment of, 316
in Cushing's syndrome, 555–558
adrenocorticotropin hormone-secreting, 547–548
diagnosis of, 527–528, 557
differential diagnosis of, 566
features of, 556–557
nonfunctioning, 566
treatment of, 557–558
aldosterone-producing, 273–274
in Cushing's syndrome, in dogs and cats, 673
pituitary, in Cushing's syndrome, corticotropin-secreting, 548–551
in dogs and cats, 672
Adenomectomy, transsphenoidal, in adults, 572
in children, 635–636
Adrenal chromaffin hyperplasia, stimulation of, in MEN 2–related tumors, 196–197
transgenic mouse models of, 197–198
Adrenal gland, in Cushing's syndrome, adenoma of, 539–542, 555–558
carcinoma of, 556, 558–561, 579–580
Carney complex in, 561–562
computed tomography of, 527–530
dysplasia of, Cushing's syndrome from, 301–302
primary pigmented, 556, 559–562
hyperplasia of, macronodular, 527–528, 530, 556, 562–565. See *Macronodular adrenal hyperplasia (MAH).*
primary pigmented nodular disease of, 528–530
masses in, evaluation of, 542–543
incidental, 566–567
Adrenal medulla, in MEN 2. See *Pheochromocytoma.*
Adrenal tumors, in MEN 1, genes in, 76
Adrenalectomy, for MEN 2 syndromes, 224, 226
for pheochromocytoma, anterior versus posterior approach in, 173–174
bilateral versus unilateral, 169–172
laparoscopic, 173
pharmacologic preparation for, 172–173
subtotal, 172
in Cushing's syndrome, bilateral, 572–573
in children, 635
in dogs and cats, 928
in pregnancy, 623
subtotal with radiotherapy, 573
unilateral, 572, 580–581
in ectopic ACTH syndrome, bilateral, 592
in primary pigmented nodular adrenal dysplasia, 561

α_1-Adrenergic blockers, for pheochromocytic hypertension, 399–401
α_1-Adrenergic receptor blockers, for obesity-associated hypertension, 419
Adrenocorticotropin hormone (ACTH). See also *Ectopic adrenocorticotropin hormone (ACTH) syndrome.*
  immunoreactive assay for, in Cushing's syndrome, 520–521
  in physiology of HPA axis, 454
  inferior petrosal sinus sampling of, for Cushing's syndrome, 310–311
  plasma level of, in Cushing's syndrome, in children, 633
    in dogs and cats, 928
    measurement of, 473–474
  plasma levels of, in Cushing's syndrome, 309–310
  proopiomelanocortin and, as precursor of, 467–469
    effect on, 472
  sampling of, inferior petrosal sinus, 519
  secretion of, abnormal, 586
    normal, 585–586
Affective disorders, in Cushing's syndrome, 4
Aging, hypogonadism from, male, 781–782
Aldosterone, licorice-induced hypertension and, 362–363
Aldosteronism, glucocorticoid-remediable, **285–297**
    clinical features of, 285–286
    future directions in, 295
    gene mutation in, 290–294
    hypertension and, low renin essential, 431–432
    pathophysiology of, 287–288
    steroidogenesis in, 288–290
    treatment of, 294–295
  primary, **271–283**
    clinical manifestation of, 271–275
    diagnosis of, 271–275
    therapeutic approaches to, pathophysiology and, 275–280
    treatment of, 280–282
Alkylating drugs, gynecomastia from, 830
Amiloride, for 11β-hydroxylase deficiency, 334
Aminoglutethimide, for Cushing's disease, 314
  for Cushing's syndrome, 579
  for ectopic ACTH syndrome, 592–594
Amniotic fluid analysis, for prenatal diagnosis of 11β-hydroxylase deficiency, 335–336
Amyloidosis, cutaneous lichen, MEN 2A-associated, 142–143
Androgen(s), deficiency of, erectile dysfunction in, 776
    gonadotropins for, 868–871
  for hypogonadism, 866–868
    17α-alkylated, oral, 866, 868
    side effects of, 867–868
    testosterone 17β-hydroxyl esters, 860–864
  in aging men, body composition and, 880–881
    bone and, 879–880
    cognitive function and, 882
    hematopoiesis and, 881
    immune system and, 883
    lipids and, 882
    mood and, 882
    replacement of, body composition and, 884–885
      bone and, 883–884
      hematocrit and, 885
      methods in, 886
      mood/cognitive function and, 885
      prostate and, 885–886
    serum levels of, 877–879
    sexual function and, 882
    target organs of, 879–883
  in contraception, 897–899
  5α-reduced, in testicular function, 716–717
  replacement of, evaluation of aging men for, 886–887
    for erectile dysfunction, 780
    in hypogonadism, 767
Andrology, **699–922**
  androgen administration to aging men, **877–892**
  benign prostatic hyperplasia in, **795–807**
  erectile dysfunction in, **773–782**
  gynecomastia in, **825–837**
  history and physical examination in, **709–707**
  hypogonadism in, **749–772**
    hormonal therapy for, **857–875**
  male contraceptives and, hormonal, **893–922**
  male infertility in, **783–793**
  medical history in, 699–702
    developmental, 700
    exposures in, 700
    general, 700–702
    medications in, 701
    testicular dysfunction in, risk factors for, 700
  physical examination in, for gynecomastia, 702–703
    for virilization, degree of, 702–703
    general features of, 705
    genital and testicular, 703–704
    of prostate, 707–705
    rectal, 704–705
  prostate cancer in, **809–824**
  seminal fluid analysis and sperm function testing in, **725–748**

sexual history in, 702
testicles in, dysfunction of, in systemic disease, 839–856
function of, 709–723
Angiography, magnetic resonance, for renovascular hypertension, 246
Angiotensin II, hypertension and, essential, low-renin, 430–431
renovascular, 241
Angiotensin-converting enzyme (ACE) inhibitors, for 11β-hydroxylase deficiency, 335
for hypertension, obesity-associated, 418–419
renovascular, 242, 244, 246
Antiandrogen, for male contraception, 908–909
Antidepressants, tricyclic, erectile dysfunction from, 777
Antiestrogens, in evaluation of hypothalamic-pituitary-testicular unit, 718
Antihypertensives, erectile dysfunction from, 777
for 11β-hydroxylase deficiency, 334–335
for obesity-associated hypertension, 418–420
for renovascular disease, 242, 244
Arginine vasopressin (AVP), in autoimmune disease, 458–459
in hypothyroidism, 458
in physiology of HPA axis, 457–458
Aromatase enzyme, in gynecomastia, 826–827
Arteriography, selective renal, for localization of juxtaglomerular apparatus tumors, 259
Aspergillosis, risk for, glucocorticoids and, 662
Atherosclerosis, erectile dysfunction in, 776–777
of renal artery, 235–249
Atherosclerotic disease, in Cushing's syndrome, 499
Autoimmune disease, inflammatory, HPA axis in, 458
testicular dysfunction in, 848–849
AVP. See *Arginine vasopressin (AVP).*

Benign prostatic hyperplasia, 795–807
epidemiology of, 796
pathogenesis of, 769–798
hormonal theories of, 797–798
stem cell in, 798
stromal-epithelial interaction in, 798
pathology of, 795–796
Benign prostatic hypertrophy (BPH), diagnosis of, post-void residual in, 798–799
prostate size and, 798–799
urodynamic testing in, 798
pharmacotherapy for, antiandrogens, 801–803
atamestane in, 802–803
α-blockade, selective, 803–804
finasteride in, 802
selection of, 804
surgery for, 800–801
symptoms of, 798–799
treatment of, indications for, 800
selection of, 804
Biguanides, for obesity-associated hypertension, 419
Bioassays, of gonadotropins, 6
versus functional assays, of sperm function, 740–742
Bisphosphates, for osteoporosis, 650
Blood, disorders of, in Cushing's syndrome, 490, 497–498
Body composition, in aging men, androgen replacement and, 880–881, 884–885
Bone, glucocorticoids and, in loss of, 641–645
in turnover of, 645–646
in aging men, androgen replacement and, 879–880, 883–884
Bone mineral density, determination of, in osteoporosis, 648
BPH. See *Benign prostatic hyperplasia (BPH); Benign prostatic hypertrophy.*
Bronchus, carcinoid tumors of, in Cushing's syndrome, 531–532
Bruising, in Cushing's syndrome, in dogs and cats, 683–684

Calcinosis cutis, in canine Cushing's syndrome, 680, 685
Calcitonin, as tumor marker, for MEN syndromes, 216–217
for osteoporosis, 650
serum, in medullary thyroid carcinoma, MEN 2–associated, 161–162
Calcitonin gene, RNA processing of, in medullary thyroid carcinoma, 201–202
Calcium, in multiple endocrine neoplasia 2A, screening for, 11
insulin resistance and, in hypertension, 416
Calcium channel blockers, for 11β-hydroxylase deficiency, 334–335
for 17α-hydroxylase deficiency, 354
for hypertension, obesity-associated, 419
Candidiasis, risk for, glucocorticoids and, 663
Carbenoxolone, hypertension and, licorice-induced, 359

Carbenoxolone *(Continued)*
licorice and, effects of, 366–369
Carcinoids, in MEN 1, 59
genes and, 76
Carcinoma, adrenal, Cushing's syndrome from, 301
treatment of, 316
adrenocortical, chemotherapy for, 579–580
clinical features of, 556, 558–559
diagnosis of, biochemical, 558
radiologic, 559
differential diagnosis of, 566
in dogs and cats, 673
radiotherapy for, 579–580
surgery for, 572, 579
Cardiovascular system, in Cushing's syndrome, 490, 498–499
Carney complex, in primary pigmented nodular adrenal dysplasia, 561–562
CASA (computer-assisted sperm analysis), 729–732
Catecholamine metabolism, in pheochromocytoma, 200–201
normal, 200
Catecholamines, diagnostic, for pheochromocytoma, 395
C-cell hyperplasia, medullary thyroid carcinoma and, 157–158
stimulation of, in MEN 2–related tumors, 196–198
C-cells, in medullary thyroid carcinoma, 140
Cholelithiasis, pheochromocytoma with, 393
Chromosome 10, gene localization to, in familial medullary thyroid carcinoma, 180–181
in MEN 2A, 178–180
in MEN 2B, 179–181
mapping of, crossovers in, 182
linkage analysis in, 178–182
Chromosome 11, mapping of, in MEN 1, 99–104, 111–113
Cirrhosis, hepatic, hypogonadism from, male, 766
Clitoroplasty, for congenital adrenal hyperplasia, 335
Clonidine suppression test, diagnostic, for pheochromocytoma, 397
CMV. See *Cytomegalovirus (CMV) infection.*
Cognition. See *Mental function.*
Cognitive function, in aging men, androgen replacement and, 882, 885
Coitus, disorders in, infertility from, 789–790
Computed tomography, of juxtaglomerular apparatus tumors, 259
of pheochromocytoma, 397–398
of tumors causing Cushing's syndrome, 312
Computer-assisted sperm analysis (CASA), 729–732
Congenital adrenal hyperplasia, from steroid 11β-hydroxylase deficiency, 325–339
Contraceptives, male, **893–922**
acceptability of, 894–895
demand for, 893–894
endocrine approach to, 904–905. See also specific hormone, e.g., *Androgen.*
androgen only, 897–899
antiandrogens, 908–909
barriers to, 910–911
FSH immunization, 909
GnRH agonists, 901–903
GnRH antagonists, 903, 906–908
inhibin, 909
risks and benefits of, long-term, 909–910
sites for, 896–897
steroid combinations, 899–901
spermatogenesis and, endocrine control of, 894
process of, 895–896
Corticosterone methyloxidase deficiency, 336
Corticotropin, in physiology of hypothalamic-pituitary-adrenal axis, 452–453
Corticotropin-releasing hormone (CRH), in Cushing's syndrome, pathogenesis of, 548–550
placental, 622–623
in physiology of hypothalamic-pituitary-adrenal axis, 452–454
in psychiatric disorders, 457–458
Corticotropin-releasing hormone (CRH) stimulation test, for Cushing's syndrome, **451–691**
in adults, 515–517, 524–525, 597–598
in children, 634
for ectopic ACTH syndrome, 590
Corticotropin-releasing hormone (CRH) syndrome, ectopic, Cushing's syndrome from, 301
treatment of, 315–316
Cortisol, excess of, in Cushing's syndrome, 490, 499–500
in pseudo-Cushing states, 517–518
excess of. See also entries under *Hypercortisolism.*
24-hour test of, in children, 632–633
monitoring of, in pharmacotherapy of Cushing's syndrome, 574–576
plasma level of, in adrenal carcinoma, 558
urine free, in Cushing's syndrome, 511–513

CRH. See *Corticotropin-releasing hormone (CRH).*
Cryptococcosis, risk for, glucocorticoids and, 663
Cryptorchidism, 759
Cushing's disease, Cushing's syndrome in, 300–301
  pituitary adenoma in, **925–699.** See also *Pituitary adenoma.*
  treatment of, 312–314
Cushing's syndrome, **451–691.** See also *Pseudo-Cushing states.*
  ACTH-related, 563, 656
  adrenal gland-related, nodular, **555–569**
    adenomatous, 555–558
    carcinomatous, 556, 558–561
    Carney complex in, 561–562
    differential diagnosis of, 566–567
    macronodular hyperplastic, 556, 562–565
    McCune-Albright syndrome in, 565
    primary pigmented dysplastic, 556, 559–562
  patient evaluation for, algorithm for, 565
  clinical features of, 490–500
    cardiovascular, 498–499
    cutaneous, 491, 493–495
    endocrinologic, 499–500
    gastroenterologic, 499
    hematologic, 497–498
    immunologic, 497–498
    in bone and joint, 496
    in dogs and cats, 674–685
    in hair, 495
    in pregnancy, 619–620
    metabolic, 500
    muscular, 495–496
    neurologic, 497
    obesity, 490–493
    ophthalmologic, 496–497
    patient perspective of, 608–610, 613–614
    psychologic, 497
  corticotropin-releasing hormone-mediated, 452–454, 457–458, 538–540, 594, 597–598
  corticotropin-releasing hormone stimulation test in, 515–517, 524–525, 634
  cortisol in. See also *Cortisol.*
  dexamethasone suppression tests for, in adults, 512–515, 517, 521–524
    in children, 632–634
    in dogs and cats, 688
  diagnosis of, **511–537**
    biochemical, in adults, 511–527
      in children, 631–635
      in dogs and cats, 688
    diurnal rhythm in, 515–516
    in pregnancy, 620–621
    problems in, 517–519
    radiologic, in adults, 527–537
      in children, 634
      in dogs and cats, 686–687
  differential diagnosis of, 519–527
  epidemiology of, **539–546**
  evaluation for, patient selection in, 500–502, 543
  glucocorticoid action in, 487–489
  hypertension and, **299–324**
    clinical features of, 302–307
    diagnosis of, 307–312
    etiology of, 299–302
    response to correction of hypercortisolism, 316–317
    treatment of, 312–316
  in children, **629–639**
    clinical presentation of, 630–631
    diagnosis of, biochemical, 631–634
      inferior petrosal sinus sampling in, 634–635
      radiologic, 634
    incidence of, 629–630
    treatment of, in recurrent or persistent disease, 636
      primary, 635–636
      response to, 637
  in dogs and cats, **671–691**
    diagnosis of, biochemical, 688
      clinicopathologic, 685–686
      imaging in, 686–687
    etiology of, 671–674
    in hyperadrenocorticism in, 671–680
    prognosis in, 689
    treatment of, 688–689
  in pregnancy, **619–627**
    case report of, 621–622
    clinical features of, 619–620
    complications in, fetal, 623
      maternal, 620, 623
    corticotropin-releasing hormone in, placental, 622–623
    laboratory studies and diagnoses in, 620–621
    treatment of, 623–624
  incidence of, 489
  inferior petrosal sinus sampling in, in adults, 519, 525–527
    in children, 634–635
  pathogenesis of, **547–554**
    hypothalamic theory of, 547–548
    pituitary theory of, 549–550
    studies of, clonality tissue, 550–551
  patient perspective study in, **607–617**
    family in, 611, 614–616
    help with coping in, 612, 615–616
    impact of, overall, 609
    mental effects in, 610–611, 614, 616
    patients and methods in, 607–608
    physical effects in, 608–610, 613–614

Cushing's syndrome *(Continued)*
recovery in, 613, 615
work or school performance in, 612, 614–615
subclinical versus preclinical, 540–542
treatment of, adrenal gland-directed, **555–569**
in children, 635–637
in dogs and cats, 688–689
in pregnancy, 623–624
pharmacotherapy in, 573–580
radiotherapy in, 579–580
surgery in, 571–573
Cutaneous lichen amyloidosis, in MEN 2A, 142–143
CYP11B1 mutations, 11β-hydroxylase deficiency from, 332–333
Cytokines, in bone loss, glucocorticoid-induced, 643–644
inflammatory, in physiology of HPA axis, 455–456
Cytomegalovirus (CMV) infection, risk for, glucocorticoids and, 663–664

Del Castillo's syndrome. See *Sertoli cell only (Del Castillo's) syndrome.*
Deoxycorticosterone, 17α-hydroxylase deficiency and, 341
activity of, 349–350
and hypertension, mineralocorticoid, 350–351
Depression, in Cushing's syndrome, 610–611, 614
DES (diethylstilbestrol), for prostate cancer, 819
Dexamethasone, for 17α-hydroxylase deficiency, 353
Dexamethasone suppression test(s), for Cushing's syndrome, comparison of, high-dose and low-dose, 522–523, 544
high-dose, in adults, 521–522
in children, 633
in dogs and cats, 688
intravenous, in adults, 513–514
in children, 634
Liddle, 513
low-dose, in adults, 543
in children, 632
in dogs and cats, 688
overnight, 1 mg, 512–513
8 mg, 522
for ectopic ACTH syndrome, high-dose, 589
high-dose, for Cushing's syndrome, 310
Dexfenfluramine, for obesity-associated hypertension, 419
Diabetes insipidus, in Cushing's syndrome, in dogs and cats, 677
Diabetes mellitus, erectile dysfunction in, 792
Diethylstilbestrol (DES), for prostate cancer, 819
Digital rectal examination (DRE), for prostate cancer, diagnostic, 813–814
screening, 815–817
Dihydrotestosterone (DHT) hypothesis, for benign prostatic hypertrophy, 797
Diuretics, for osteoporosis, 649
DNA probes, in molecular genetics, 120–121
DRE. See *Digital rectal examination (DRE).*

Ectopic adrenocorticotropin hormone (ACTH) syndrome, clinical features of, 588
Cushing's syndrome from, 301
diagnosis of, biochemical, 589–591
CRH-mediated, **585–606**
inferior petrosal sinus sampling in, 590–591
peptides in, co-secretion of, 590
radiologic, computed tomography in, 591
expression of ACTH and, 585–586
in dogs and cats, 673
mineralcorticoid excess in, 371
treatment of, adrenalectomy in, 315–316
chemotherapy in, 592–596
tumors in, benign and malignant, 586–588
Electrolytes, imbalance of, in Cushing's syndrome, 500
End-stage renal disease, from renovascular disease, 244
Epididymis, obstruction of, infertility from, 786–787
Epilepsy, temporal lobe, testicular dysfunction in, 846–847
Erectile dysfunction, **773–782**
cavernosal factors in, 777
diagnosis of, 778–780
laboratory testing in, 778–779
ultrasonography in, 779–780
vascular evaluation in, 779
drug-induced, 777–778
erection and, hemodynamics of, 774
neurovascular pathways in, 774–775
physiology of, 773–774
impotence, 775–777
treatment of, 780–781
Erythropoietin, hypertension and, renovascular, 241
Essential hypertension, **427–443.** See also *Hypertension, essential.*
Estrogen:androgen ratio, in gynecomastia, 826–828

Estrogen/androgen synergism theory, for benign prostatic hypertrophy, 797–798
Estrogens, in testicular function, 716
Etidronate, for osteoporosis, 649
Exercise, for hypertension, obesity-associated, 417–418
for osteoporosis, 648
Eye, in Cushing's syndrome, 490, 496–497
cataracts in, 497
intraocular pressure elevation in, 496–497

Face, in Cushing's syndrome, 492–493
Familial hypocalciuric hyperparathyroidism (FHH), mechanism of, molecular, 103
Familial medullary thyroid carcinoma (FMTC), inherited defect in, mapped to chromosome 10, 180–181
Fat, deposition of, in Cushing's syndrome, abdominal, 491–492
in cheeks, 492
in epidural space, 493
Fatigue and weakness, in Cushing's syndrome, in adults, 609–611, 613–615
in dogs and cats, 675, 678–679
Fenfluramine, for hypertension, obesity-associated, 419
Fertile eunuch syndrome, 762, 789
FHH (familial hypocalciuric hyperparathyroidism), mechanism of, molecular, 103
Fluoride, for osteoporosis, 649
FMCT (familial medullary thyroid carcinoma), inherited defect in, mapped to chromosome 10, 180–181
Follicle-stimulating hormone (FSH), deficiency of, 762
immunization of, for male contraception, 909
in testosterone regulation, 713
secretion of, inhibin in, 717–718
Fragile X syndrome, testicular dysfunction in, 846

Ganglioneuromatosis, mucosal, in MEN 2B, 145–146
Gastrin, in MEN-1, screening for, 11–14
Gastrinomas, in MEN 1, 55–56
Genital tract, male, obstruction of and infertility, 786–787
Glomerular filtration rate, renin-angiotensin system and, 240
Glucagon, diagnostic, in pheochromocytoma, 395, 397
Glucagonoma, in MEN 1, 58
Glucocorticoids, action of, in Cushing's syndrome, 487–489
and infection, **655–670**
anti-inflammatory and immunosuppressive effects in, 655–656, 660, 664
bacterial, 661
fungal, 658–659, 662–663
mycobacterial, 661
parasitic, 661–662
prevention of, 664–665
risk of, host factors in, 658–659
in Cushing's syndrome, 659
in ectopic ACTH syndrome, 659–660
pharmacologic factors in, 657–658
viral, 663–664
and osteoporosis, **641–654.** See also *Osteoporosis, glucocorticoid-induced.*
bone turnover and, 645–646
diuretics in, 649
excess exposure to, patient care in, 664–665
preventive health care in, 664–665
for aldosteronism, glucocorticoid-remediable, 294–295
for 11β-hydroxylase deficiency, 333–334
for 17α-hydroxylase deficiency, 353–354
in bone loss, cytokine role in, 643–644
insulin-like growth factor and, 644
insulin-like growth factor binding proteins and, 644–645
osteoblasts and, 642–643
remodeling cycle and, 641–642
vitamin D effects and, 643
in physiology of HPA axis, 454–455
replacement, after adrenalectomy, 573
Gonadal dysgenesis, male, XX, 754
XX/XO, 754
Gonadotropin deficiency, acquired, causes of, 763
congenital, syndromes associated with, 716
male, infertility from, 788–789
Gonadotropin-releasing hormone (GnRH), for hypogonadism, male, 871–872
Gonadotropin-releasing hormone (GnRH) agonists, for male contraception, controversies in, 903
mechanism of, 901–902
trials of, 902–903
Gonadotropin-releasing hormone (GnRH) antagonists, for male contraception, mechanism of, 903, 906
problems with, 908
trials of, 906–908
Gonadotropin-releasing hormone (GnRH) test, for hypogonadism and hypothalamic disorders, 718–720

Gonadotropins, bioassays and radioreceptor assays for, 715
for androgen deficiency, in hypogonadism, 868–869
in gynecomastia, 827
in testicular function, 712–714
spermatogenesis and, initiation and maintenance of, 869–871
subunits of, 714–715
Growth axis, and HPA axis, 457
Growth factor, genes and, in MEN 1, 76–77
Growth hormone (GH), circulating, in MEN 1, 76–77
secretion of, by pituitary adenomas, 43–45
Gynecomastia, 825–837
aromatase enzyme activity in, 827
causes of, 826
drug-induced, 829–830
estrogen/androgen ratio in, 826–828
gonadotropins in, role of, 827
histology of, 825
in cirrhosis, hepatic, 832
in hypogonadism, 831–832
in nutritional rehabilitation, 832
in thyrotoxicosis, 832
medications associated with, 701
nonpathologic, 828–829
pathogenesis of, hormonal, 825–828
patient evaluation in, 833
physical examination for, 702–703
treatment of, 834
tumor-associated, 830–831

Hair, in Cushing's syndrome, in dogs and cats, 675, 679–682
Hamartoma, definition of, 260
Hemangiopericytoma, definition of, 260
Hematocrit, in aging men, androgen replacement and, 885
Hematopoiesis, in aging men, androgens and, 881
Hemochromatosis, hypogonadism from, male, 766
Hemoglobinopathies, testicular dysfunction in, 847–848
Herpes simplex infection, risk for, glucocorticoids and, 663
HPA axis. See *Hypothalamic-pituitary-adrenal (HPA) axis.*
HPT. See *Hyperparathyroidism (HPT).*
Human chorionic gonadotropin (hCG), for androgen deficiency, 868–871
Human chorionic gonadotropin (hCG) stimulation test, of testosterone secretion, 718
Human chorionic gonadotropin (hCG), testosterone response to, in older men, 878

Hydrocortisone, for Cushing's disease, 314
for 11β-hydroxylase deficiency, 334
for 17α-hydroxylase deficiency, 353
11β-Hydroxylase deficiency. See *Steroid 11β-hydroxylase deficiency.*
17α-Hydroxylase/17,20–lyase deficiency, hyperaldosteronism in, 351–353
11β-Hydroxysteroid dehydrogenase deficiency, as syndrome of apparent mineralocorticoid excess, 363–364
Hyperadrenocorticism. See also *Cushing's syndrome.*
pituitary-dependent, in dogs and cats, 671–674
Hyperaldosteronism, glucocorticoid-suppressible, 336–337
in 17α-hydroxylase/17,20–lyase deficiency, 351–353
Hypercalcemia, pheochromocytoma and, 392
Hypercortisolism, chemotherapy for, 580
clinical findings in, 490–500. See also *Cushing's syndrome, clinical features of.*
in Cushing's syndrome, 307–309, 548–549
corticotropin-releasing hormone in, 594, 598
response to correction of, 316–317
in pregnancy, 658
in pseudo-Cushing states, 517–518
psychiatric disorders in, 457–458
testicular dysfunction in, 864
versus Cushing's syndrome, 518–519
Hyperinsulinemia, hypertension and, obesity-associated, 407–409
Hyperparathyroidism (HPT), familial, benign hypocalciuric hypercalcemia with parathyroid hyperfunction, 30–31
cystic parathyroid adenomatosis with fibro-osseous tumors in, 28–29
dominant parathyroid adenomas without jaw tumors in, 30
dominant parathyroid hyperplasia without other endocrinopathy in, 30
hypocalciuric, 103
in MEN 1, 19–27
in MEN 2A, 27–28
parathyroid hyperplasia with recessive or uncertain transmission, 31–33
transmission of, 30
in MEN 1, clinical signs and symptoms of, 20–21
description of, 19–20
diagnosis of, 21
familial, 19–27
medical treatment of, 26–27

missed hyperfunctioning gland in, approaches to, 25–26
parathyroid hormone in, ectopic, 104
surgery for, 22–25
tumor suppressor genes in, 99–101
in MEN 2, familial, 27–28
in MEN 2A, 102, 144–145, 150
incidence of, 224
management of, 27–28
surgery for, 224
in MEN 2A and MEN 2B, comparison of, 164–165
Hyperplasia, adrenal, 527–530
in MEN 2–related tumors, 196–198
pituitary, in dogs and cats, 673
Hypertension. See also specific, e.g., *Aldosteronism, primary.*
Cushing's syndrome and, **299–324**
clinical features of, 302–307
diagnosis of, 307–312
etiology of, 299–302
response to correction of hypercortisolism, 316–317
treatment of, 312–316
endocrine, **235–449**
essential, **427–442**
insulin-resistance in, 437–439
mechanisms of, 430–432
nonmodulators of, 432–436
renin-angiotensin system in, 428–430
renin-angiotensin-aldosterone axis in, 427–428
from 11β-hydroxylase deficiency, 330
from pheochromocytoma, **387–404**
from renin-secreting tumors, 255–270
in Cushing's syndrome, 498–499, 609–610, 614
in thyroid disorders, **379–386**
hyperthyroidism and, 382–383
hypothyroidism and, 379–382
licorice-induced, **359–377**
and syndromes of apparent mineralocorticoid excess, **359–377**
clinical and biochemical features of, 360–361
current controversies in, 366–373
historic uses of licorice, 359–360
mechanisms of mineralocorticoid excess in, 361–366
mineralocorticoid, deoxycorticosterone and, 350–351
obesity and, **405–426**
definition in, 406–407
diagnosis and treatment of, 416–420
evidence for association between, 405–406
pathophysiology of, 407–416
renovascular, **235–253**
clinical presentation of, 236–237
diagnosis of, 244–246
incidence of, 235–236
management of, 246–248
pathophysiology of, 237–244
with aldosteronism, glucocorticoid-remediable, 285–297
primary, **271–283**
with 11β-hydroxylase deficiency, 325–339
with 17α-hydroxylase deficiency, 341–357
Hyperthyroidism, hypertension in, antithyroid therapy and, 383
mechanism in, 383–384
prevalence of, 382–383
hypertension with, 382–384
Hypogonadism, and 17α-hydroxylase deficiency, 345
androgen replacement therapy for, 767–768
gynecomastia in, 831–832
hypogonadotropic, 761. See also *Hypogonadism, hypogonadotropicism*
classic, 761–765
description of, 761–762
from irradiation, cranial, 765
from pituitary adenomas, prolactin-secreting, 764
from systemic illness, 764
from trauma, cranial, 764
gonadotropin deficiency in, acquired, 762–764
isolated LH or FSH, 762
syndromes with, 763
treatment of, 762
male, **749–772**
classification of, 750
cryptorchidism in, 759
definition of, 749
diagnosis of, 749–750
from chemotherapy, 760
functional prepubertal castrate, 755
hormonal therapy for, **857–875**
androgens in, 860–868
contraindications to, 860
GnRH therapy for, 871–872
goals of, 858–860
gonadotropins in, 868–871
in enzymatic defects of testosterone biosynthesis, 755–756
in Klinefelter's syndrome, 752–754
in leprosy, 759–760
in LH-resistant testis, 757
in myotonic dystrophy, 754–755
in orchitis, postpubertal, 759
in persistent müllerian syndrome, 757
in 5α-reductase deficiency, 756–757
in Reifenstein's syndrome, 758–759
in Sertoli cell only syndrome, 755
in XX chromosomal constitution, 754
in XX/XO gonadal dysgenesis, 754

Hypogonadism *(Continued)*
in XYY syndrome, 754
physiology in, testicular, 858
primary, 751–761
pseudohermaphrodism in, from androgen receptor defects, 757–758
testicular, autoimmune, 760
feminization in, 758
from irradiation, 760
from trauma, 760
testicular androgen failure in, manifestations of, 751
treatment of, 861
hormonal, 860–872. See also named, e.g., *Androgens.*
nonhormonal, 872–873
primary and secondary combined, aging and, 765–766
from cirrhosis, hepatic, 766
from hemochromatosis, 766
from sickle cell disease, 766
in obesity, 767
secondary, 761
Hypokalemia, in primary aldosteronism, 272
Hypothalamic-pituitary-adrenal (HPA) axis, pathophysiology of, 457–460
in depression, 457–458
physiology of, ACTH in, 454
arginine vasopressin in, 452–454
corticotropic-releasing hormone in, 452–454
corticotropin in, pituitary, 452–453
glucocorticoids in, 454–455
growth axis in, 457
immune system interactions in, 455–456
in psychiatric and autoimmune disorders, **451–466**
neuroendocrine system interactions in, 455–456
reproductive axis in, 456–457
thyroid axis in, 457
Hypothalamus, in Cushing's syndrome, pathogenesis of, 547–548
Hypothyroidism, hypertension in, mechanism of, 380–382
prevalence of, 379–380
thyroid replacement in, 380
hypertension with, 379–382

ICSI (intracytoplasmic sperm injection), in assisted reproduction, 791–792
IGFSPs (insulin-like growth factor binding proteins), glucocorticoid effect on, 644–645
IGFs. See *Insulin-like growth factors (IGFs).*
Immune system, disorders of, in Cushing's syndrome, 490, 497–498
in aging men, androgen and, 883
interactions with HPA axis, 455–456
Immunosuppression, from glucocorticoid excess, 655–656. See also *Glucocorticoids, and infection.*
Impotence, arteriogenic, 776–777
cavernosal, 777
endocrinologic, 775–776
medications associated with, 701
neurogenic, 776
psychogenic, 775
In situ hybridization, of renin juxtaglomerular cell tumor, 261
In vitro fertilization (IVF), for male infertility, 791–792
Inferior petrosal sinus sampling (IPSS), for ACTH, 519
for Cushing's syndrome, with corticotropin-releasing hormone stimulation, in adults, 519, 525–527
in children, 634–635
for ectopic ACTH syndrome, 590–591
limitations of, 527
Infertility
male, **783–793,** 785–791
assisted reproductive technology for, 791–792
clinical evaluation of, 783–784
definition of, 783
gonadotropin deficiency in, 788–789
hormone measurements in, 785
investigation of, 784–785
obstruction and, 786–787
semen analysis in, 784–785
seminiferous tubule failure in, 785–786
sperm autoimmunity in, 787–788
sterility in, untreatable, 785–786
subfertility in, untreatable, 780–781
treatable, potentially, 786–790
Inhibin, for male contraception, 909
in testicular function, 717–718
Insemination, donor, 786
Insulin resistance, in hypertension, 410–411
endothelial function in, 413–416
essential, 437–439
obesity and, 407–410
Insulin-like growth factor binding proteins (IGFBPs), glucocorticoid effect on, 644–645
Insulin-like growth factors (IGFs), glucocorticoid effect on, 642–643
Insulinoma, in MEN 1, 57–58
Intercavernous injection, for erectile dysfunction, 778–780
Interleukin-1 (IL-1), in bone loss, glucocorticoid-induced, 643
Interleukin-6 (IL-6), in bone loss, glucocorticoid-induced, 643
Intracytoplasmic sperm injection (ICSI), in assisted reproduction, 791–792

Intravascular volume, primary aldosteronism and, 275–277
IPSS. See *Inferior petrosal sinus sampling (IPSS).*
Irradiation, hypogonadism from, male, 765
Islet cell tumor(s), in MEN 1, clinical presentation of, 54
genes in, 74–75
historical perspective on, 53
hormonal syndromes in, 54–55
pathology of, 55
treatment of, biotherapy in, 61
chemotherapy in, 61–62
hepatic artery embolization in, 61
surgery in, 60–61
types of, carcinoids, 59
gastrinoma, 55–56
glucagonoma, 58
insulinoma, 57–58
polypetideoma, pancreatic, 59
somatostatinoma, 59
vasoactive intestinal peptidoma, 59
in MEN, **53–65**
MEN 1–related and sporadic, incidence of, 110
molecular mechanisms of, **109–115**
cytogenetics in, 113
oncogenes in, 113
tumor suppressor genes in, 111–113
types of, 110
IVF (in vitro fertilization), for male infertility, 791–792

Jewett-Whitmore staging system, modified, for prostate cancer, 811–812
Juxtaglomerular apparatus, tumors of, primary reninism from, 255–260

Kallmann's syndrome. See *Hypogonadism, hypogonadotropic.*
Kennedy's disease, testicular dysfunction in, 846
Ketoconazole, for Cushing's disease, 314
for Cushing's syndrome, 575, 577
for ectopic ACTH syndrome, 594–595
Klinefelter's syndrome, 752–754
laboratory findings in, 753
phenotypic manifestations of, 752–753
treatment of, 753–754

Leprosy, effect on testes, 759–760
LHRH (luteinizing hormone-releasing hormone) agonists, for prostate cancer, 819–820
Licorice-induced hypertension, **359–377.** *See Hypertension, licorice-induced.*
Linkage studies, in MEN 1, 122, 124
age of onset and, 124, 126, 128–130
DNA sequence polymorphisms in, 126–127
LOD scores in, 124, 126
restriction fragment length polymorphisms in, 121–123, 125–127
in MEN 2A, early, 178
mapping of, 178–180
in MEN 2B, mapping of, 180–181
Lipid profile, abnormalities in, with male contraceptives, 909–910
Lipids, in aging men, androgen, androgen replacement and, 882, 885
in Cushing's syndrome, 500
Lipomatosis, spinal, in Cushing's syndrome, 4
Liver, disease of, testicular dysfunction in, 843–844
Luteinizing hormone (LH), deficiency of, in hypogonadotropic hypogonadism, 762
in testosterone regulation, 712–714
Luteinizing hormone-releasing hormone (LHRH) agonists, for prostate cancer, 819–820

Macronodular adrenal hyperplasia (MAH), in Cushing's syndrome, 301– 302
differential diagnosis of, 566
features of, 556, 562–563
in dogs and cats, 673
pathogenesis of, 563, 565
treatment of, 316, 565
Magnetic resonance angiography, for renovascular hypertension, 246
Magnetic resonance imaging, of pheochromocytoma, 397–398
of tumors causing Cushing's syndrome, 312
MAH. See *Macronodular adrenal hyperplasia (MAH).*
Malignancy, testicular dysfunction in, 845
Mapping, to chromosome 10, in MEN 2A, 178–180
in MEN 2B, 180–181
to chromosome 11, in MEN 1, 69–70, 72–73, 99–104
tumor deletion and, 120–123
Marfanoid habitus, in MEN 2B, 145
McCune-Albright syndrome, 565
Medullary thyroid carcinoma (MTC), in MEN 2, 138
pathology of, 157–158
in MEN 2A, clinical presentation of, 141–142

Medullary thyroid carcinoma (MTC) *(Continued)*
diagnosis of, age and, 159–160
calcitonin levels in, 161–162
pentagastrin stimulation test in, 159, 162
occurrence of, 140–141
pathology of, 140
prognosis of, 150–151
screening for, family history in, 147
surgery for, prophylactic, 225
in MEN 2B, clinical presentation of, 141–142
diagnosis of, calcitonin levels in, 161–162
pentagastrin stimulation test in, 161–162
phenotypic, 160–161
occurrence of, 140–141
prognosis of, 150–151
screening for, biochemical, 148–149
versus in MEN 2A, 146–147
molecular abnormalities in, biologic, cell differentiation, 198–200, 202–204
hyperplasia, 196–198
genetic, 194–195
RET gene mutation and, 189–194
RNA processing of calcitonin gene, 201–202
inherited defect in, 189–194
thyroidectomy for, follow-up of, 164
in early stage disease, 163–164
total, 162–163
Memory. See *Mental function.*
Mental function, in Cushing's syndrome, 497, 610–611, 614, 616
Metanephrine, diagnostic, in pheochromocytoma, 395
in pheochromocytoma, MEN 2–associated, 168–169
Metformin, for hypertension, obesity-associated, 419
Metyrapone, for Cushing's disease, 314
for Cushing's syndrome, in adults, 574–576, 580
in pregnancy, 624
for ectopic ACTH syndrome, 592–594
Metyrapone test, for Cushing's syndrome, in children, 633–634
MIBG scintigraphy, in pheochromocytoma, 398
Micronodular adrenal dysplasia, Cushing's syndrome from, 301–302
treatment of, 316
Mifepristone (RU 486). See *RU 486 (Mifepristone).*
Mineralocorticoid excess, licorice-induced, mechanism of, 361–366
syndromes of apparent, licorice-induced hypertension and, **359–377.** See also *Hypertension, licorice-induced.*
Mineralocorticoids, replacement of, after adrenalectomy, 573
Mitotane, for Cushing's disease, 314
Mitotane (o,p'DDD). See *o,p'DDD (Mitotane).*
Molecular genetics, in MEN 2A, 178–180
in MEN 2B, 180–181
mapping studies in, in MEN 1, 69–70, 72–73, 99–104, 120–123
of neoplasia, 118–121
chromosomal mechanisms in, 119
DNA probes in, 120–121
mutations in, 118–121
oncogenes in, 118–119
tumor suppressor genes in, 119
Mood, in aging men, androgen replacement and, 882, 885
MTC. See *Medullary thyroid carcinoma (MTC).*
Multiple endocrine neoplasia (MEN), **1–228**
type 1, **1–18**
associated tumors in, genes in, 71–73
clinical features and screening in, **1–18**
clinical features of, 2–6
adrenocortical carcinoma, 5–6
duodenal tumors, neuroendocrine carcinoid-like, 5
pancreatic endocrine lesion, 4–5
parathyroid lesion, 3
pituitary lesion, 3–4
gene for, **67–79**
genes in, candidate, identification of, 70–71
circulating growth factor and, 76–77
in adrenal tumors, 76
in carcinoid tumors, 76
in pancreatic tumors, 74–75
in parathyroid tumors, 73–74
in pituitary tumors, 75
in thyroid neoplasia, 76
localization and identification of, **67–79**
on chromosome 11, fine mapping of, 69–70, 72–73
long arm of, 67–69, 71
genetic screening for, molecular, **117–135**
historical perspective in, 1–2
hyperparathyroidism in, **19–36**
islet cell tumors in, **53–65, 109–115**
molecular genetics and, **117–135**
parathyroid neoplasia in, **93–107**
pituitary neoplasia in, **37–51, 81–92**
prognosis in, 6–7
screening for, **1–18, 117–135**
biochemical, 9–10, 127–130
programs for, 10–15
DNA markers for, 130–132
family in, 8, 10–11

genetic, deletion mapping in, 120–123
genetic principles in, 8–10
in high-risk individuals, criteria in, 132
linkage studies in, 122, 124–129
reasons for, 7–8
tumors in, 118–119
biochemical features of, 118
type 2, **137–156**
adrenal medullary disease in, **167–176**
associated tumors in, molecular abnormalities in, **187–213**
characteristics of, 138–139
classification of, 137–138
clinical features and screening of, **137–156**
clinical presentation of, 139
in type 2A, 139–145
in type 2B, 145–147
diagnosis and management of, current, **215–228**
diagnosis of, biologic, provocative testing in, 216–217, 225–226
genetic, DNA mutational analysis, 221–222, 226
linkage analysis in, 217–219
RET mutations, 218–221
screening and counseling of family in, 221–224
future of, 152
historical perspective on, 215–216
mapping inherited defects in, **177–185**
medullary thyroid tumors and hyperparathyroidism in, **157–166**
molecular abnormalities in, **187–213.** See also *RET oncogene.*
biologic, 195–204
hyperplasia, 196–198
in catecholamine metabolism, 200–201
in cell differentiation, 198–200, 202–204
in RNA processing, 201–202
genetic, in tumor progression, 194–195
retinoblastoma gene, 190
in medullary thyroid carcinoma, 188–204
in pheochromocytoma, 188–189, 194–198, 200–201
prognostic factors in, 150–152
screening for, biochemical, 148–150
genetic, 147–148
procedures for, 151
surgery for, 224–226
adrenalectomy, 224, 226
parathyroidectomy, 224, 226
thyroidectomy, 224–225
type 2A, 139
clinical presentation of, 139
cutaneous lichen amyloidosis in, 142–143
hyperparathyroidism in, primary, 144–145
medullary thyroid carcinoma in, 140–142
pheochromocytoma in, 143–144
cutaneous lichen amyloidosis in, 142–143
hyperparathyroidism in, 27–28, 144–145, 164–165
inherited defects in, DNA markers of, 178–179
mapping of chromosome 10 in, 179–180
refinement of, 181–183
medullary thyroid carcinoma in, 140–142, 159–162
pheochromocytoma in, 143–144
screening for, biochemical, 148–150
genetic, 147–148
type 2B, 145–152
clinical presentation of, 145–147
marfanoid habitus in, 145
medullary thyroid carcinoma in, 140–141, 146–147
neuromas and ganglioneuromatosis in, mucosal, 145–147
diagnosis of, 160–162
inherited defects in, mapping to chromosome 10, 179–181
refinement of, 181–183
medullary thyroid carcinoma in, 159–162
pheochromocytoma in, 168–174, 392
prognosis in, 151–152
screening for, 147–149
biochemical, 148–149
genetic, 147–148
Mumps orchitis, 775
Muscle, in Cushing's syndrome, atrophy of, 495–496
in dogs and cats, 675, 678–679
Myotonia, dystrophic, in hypogonadism, male, 754–755
testicular dysfunction in, 846

Nelson's syndrome, in adults, 573
in Cushing's syndrome, in children, 636–637
in pituitary adenoma, ACTH-secreting, 934
treatment of, 314–315
Neuroendocrine system, interactions with HPA axis, 455–456
Neurofibromatosis, pheochromocytoma with, 392, 393

Neuromas, mucosal, in MEN 2B, 145–146
Nifedipine, for primary aldosteronism, 279
Nortestosterone, for male contraception, 900–901

Obesity, hypertension and, **405–426**
association between, 405–406
definitions of, 406–407
diagnosis and treatment of, 416–420
pathophysiology of, 407–416
in Cushing's syndrome, in adults, 490–493
in dogs and cats, 675, 677–678
serum testosterone in, 767
Octreotide, for ectopic ACTH syndrome, 594, 596
18-OHF, in aldosteronism, glucocorticoid-remediable, 288–290
Oncogene(s), definition of, 94–95, 189–190
in islet cell tumors, pancreatic, 113
in tumorigenesis, 118–119
PRAD1, in parathyroid adenoma, 95–99
RAS, in parathyroid tumors, 102–103
RET, in MEN 2A, 102, 189–194
o,p'DDD (Mitotane), for Cushing's syndrome, in adults, 573, 577–579
in dogs and cats, 672–673
for ectopic ACTH syndrome, 592
Orchitis, autoimmune, 849
postpubertal, 759
Osteoblasts, glucocorticoid effect on, 642–643
Osteoclasts, glucocorticoid effect on, **645–664**
Osteopenia, in Cushing's syndrome, 496
Osteoporosis, glucocorticoid-induced, **641–654**
bone mineral density in, determination of, 648
mechanisms of, 641–645
pathogenesis of, 646–647
pathophysiologic features of, 647–648
treatment of, 648–650
in Cushing's syndrome, 496, 610, 614
treatment of, etidronate in, 649
exercise in, 648
fluoride in, 649
osteoclastins in, 645–664
vitamin D in, 648–649
TH-18-OXOF, in aldosteronism, glucocorticoid-remediable, 288–290

Pancreatic islet call tumors. See *Islet cell tumor(s).*
Pancreatic polypeptide (PP), in MEN 1, screening for, 12, 14–15
Parathyroid hormone (PTH), diagnostic, for MEN 1, 21
ectopic, in hyperparathyroidism, 104
in MEN 1, 11
Parathyroid hormone (PTH) gene, in parathyroid adenomas, 95–96
Parathyroid neoplasia(s), adenoma, oncogenes in, 95–99
tumor suppressor genes in, 101–102
carcinoma, tumor suppressor genes in, 104
hyperparathyroidism in, MEN 1–associated, parathyroid hormone in, 104
tumor suppressor genes in, 99–101
hyperplasia in, sporadic primary and secondary, 111
in MEN 1, genes in, 73–74
molecular mechanisms of, **93–107**
general principles in, 93–94
oncogenes in, definition of, 94–95
PRAD1, 95–99
RAS, 102–103
RET, in MEN 2A, 102
tumor suppressor genes in, definition of, 95
in hyperparathyroidism, 99–101
in parathyroid adenomas, 101–102
in parathyroid tumors, 102–103
retinoblastoma gene, 104
Parathyroidectomy, for MEN 2 syndromes, 224, 226
for MEN 2A, 224, 226
in familial hyperparathyroidism, MEN 1, 23
Penile prosthesis, 781
Pentagastrin stimulation test, for medullary thyroid carcinoma, MEN 2A-associated, 159
MEN 2B-associated, 161–162
Pentagastrin-calcitonin stimulation test, for familial medullary thyroid carcinoma, 216
for MEN 2A and MEN 2B, 216
Percutaneous transluminal angioplasty, for renovascular hypertension, 247
Persistent müllerian duct syndrome, in hypogonadism, male, 757
Pheochromocytoma, **387–404**
clinical manifestations of, 390–393
diagnosis of, 394–398
differential diagnosis of, 393–394
in children, 392
malignant, 402–403
management of, 398–403
MEN 2A-associated, adrenalectomy for, benefit/risk of, 224, 226
clinical presentation of, 143–144
pathology and occurrence of, 143
screening for, 149–150

MEN 2–associated, adrenalectomy for, 169–174
incidence of, 171
screening for, 168–170
flow chart for, 170
scintigraphy in, 169
urinary catecholamines and, 168–169
molecular abnormalities in, biologic, hyperplasia, 196–198
in catecholamine metabolism, 200–201
genetic, 189, 194–195
origin of, 387–388
pathophysiology of, 388–390
prevalence of, 388
pHPT. See *Primary hyperparathyroidism (pHPT).*
Pituitary adenoma, in Cushing's disease, microsurgery for, 927–929
indications for, 927
remission and, 929
results of, 929–931
strategy in, 927–929
in MEN 1, 84–85
pharmacotherapy for, ACTH inhibition, 933–934
radiotherapy for, 931–933
complications of, 933
in combination therapy, 932
modalities of, 933
postoperative, 932
primary, 932
tumor localization in, 925–927
in Cushing's syndrome, macroadenoma, 927, 931
microadenoma, 529–531, 927–929
microsurgery for, complications of, 931
in recurrent disease, 928–929
in residual disease, 928
Pituitary neoplasia, in MEN 1, **37–51, 81–92, 925–934**
causes of, 81–82
classification of, 82
cytogenesis in, 83–84
description of, 81
diagnosis of, magnetic resonance imaging in, 39–42, 529–531
serum prolactin level in, 39–40
genes in, 75
growth hormone level in, 41
growth hormone-secreting, octreotide acetate for, 45–46
radiotherapy for, 46–47
surgery for, 46
historical perspective and, 37
hypothalamic-pituitary control and, hormone-secreting cells in, 82–83
occurrence of, 38–39
oncogenes in, gsp, 86
H-ras, 86–87
pituitary-activating, 85–87
pathogenesis of, 82, 549–550
prolactin-secreting, bromocriptine for, 43, 45
hypogonadism from, 764
radiotherapy for, postoperative, 44–45
surgery for, 43–45
suppressor genes in, 87–88
tumorigenesis of, 84–85
fibroblast growth factor in, 87–89
genetic changes in, 88–90
multi-step model of, 90–91
Rb suppressor gene in, 88
Pneumocystis carinii pneumonia, risk for, glucocorticoids and, 662
Polypeptideoma, pancreatic, in MEN 1, 59
Polydipsia, in Cushing's syndrome, in dogs and cats, 676–677
Polyphagia, in Cushing's syndrome, in dogs and cats, 677
Polyuria, in Cushing's syndrome, in dogs and cats, 676–677
POMC. See *Proopiomelanocortin (POMC).*
PP. See *Pancreatic polypeptide (PP).*
PPNAD. See *Primary pigmented nodular adrenal dysplasia (PPNAD).*
PRAD 1 oncogene, in nonparathyroid tumors, 98–99
in parathyroid adenoma, chromosome 11 inversion in, 95–96
cloning of, 97
overexpression of transcript in, 97
parathyroid hormone gene and, 95–96
in parathyroid carcinoma, 103–104
Primary hyperparathyroidism (pHPT), in MEN 2A, 144–145
screening for, 150
Primary pigmented nodular adrenal dysplasia (PPNAD), Carney complex in, 561–562
Cushing's syndrome in, pathogenesis of, 560–561
pathophysiologic features of, 556, 559–560
treatment of, 561
Prolactin, erectile dysfunction and, 776
in testicular function, 716
secretion of, by pituitary adenomas, 45–47
Prolactinoma, in MEN 1, 43–45
Proopiomelanocortin (POMC) peptides, **467–485**
as ACTH precursor, 467–469
biologic effects of, 472–473
circulating, in Addison's disease, 480
in chronic renal failure, 475–476
in Cushing's syndrome, 476–480

Proopiomelanocortin (POMC) peptides *(Continued)*
expression of, pituitary and nonpituitary, 470
gene of, 469–470
in plasma, ACTH, 473–474
non-ACTH, 474–475
POMC, 475–476
processing of, chemical transformation in, 471–472
proteolytic, 471
Prorennin, purification of, and biologic studies of primary reninism syndrome, 264–265
Prostaglandins, in bone loss, glucocorticoid-induced, 646
Prostate, cancer of, **809–824**
chemotherapy for, 820
diagnosis of, 813–815
epidemiology of, 809–810
hormonal therapy for, 819–820
metastasis of, 811–812
pathology of, 810–811
radiation therapy for, external beam, 818
screening for, 815–817
staging of, 811–813
intraepithelial neoplasia in, 811
systems for, 811–813
surgery for, 817–819
treatment of, controversy in, 817–818
in aging men, androgen replacement and, 884, 885–886
male contraceptives and, cancer from, 910
hypertrophy from, 909–910
Prostatectomy, for prostate cancer, 817–819
Prostate-specific antigen (PSA), diagnostic, 814–815
screening, 815–817
PSA. See *Prostate-specific antigen (PSA).*
Pseudo-Cushing states, hypercortisolism in, 517–518
versus Cushing's syndrome, 518–519
Pseudohermaphroditism, 17α-hydroxylase deficiency and, 345
male, from androgen receptor defects, 757–758
Psychotherapy, for congenital adrenal hyperplasia, 335
PTH. See *Parathyroid hormone (PTH).*

Radioreceptor assays, of gonadotropins, 715
Radiotherapy, for Cushing's disease, 313–314
for Cushing's syndrome, in adults, 579–580
in children, 635–636
Reductase deficiency, in hypogonadism, male, 756–757
Reifenstein's syndrome, 758–759
Renal artery, stenosis of, renovascular hypertension and, **235–249**
Renal failure, chronic, testicular dysfunction in, 842–843
Renin, biosynthesis of, in juxtaglomerular cell tumors, 265–266
culture of tumoral cells secreting, 266
hypersecretion of, in renal cell carcinoma, 263
in Wilms' tumor, 263
measurement of, for localization of juxtaglomerular apparatus tumors, 258–259
purification of, and biologic studies of primary reninism syndrome, 264–265
Renin juxtaglomerular cell tumor, electron microscopic studies of, 261, 262
light microscopic studies of, 261
Renin-angiotensin system, and regulation of glomerular filtration rate, 240
hypertension and, essential, 428–430
renovascular, 237–238
Renin-angiotensin-aldosterone axis, in essential hypertension, 427–428
Reninism syndrome, primary, biologic studies in, biosynthesis of human renin in juxtaglomerular cell tumors, 265–266
culture of renin-secreting tumoral cells, 266
purification of tumoral renin and prorennin, 264–265
from tumor of juxtaglomerular apparatus, 255–260
Renin-secreting tumor(s), **255–270**
biologic studies in primary reninism syndrome, 264–266
extrarenal, 263–264
histogenesis and histology of, 260–261
primary reninism from juxtaglomerular apparatus tumor, 255–260
renal cell carcinoma, 263
Wilms' tumor, 263
Renography, captopril, for diagnosis of renovascular hypertension, 245
Renovascular hypertension, **235–253.** See also *Hypertension, renovascular.*
Reproductive axis, and HPA axis, 456–457
Respiratory disease, testicular dysfunction in, 844–845
Restriction fragment length polymorphisms (RFLPs), in screening, for MEN 1, 121–123, 125–127
RET oncogene, functions of, 190–194
in MEN 2, diagnosis of, 218–221, 224

in MEN syndromes, 189
RET proto-oncogene, in MEN 2 syndromes, mutations of, 148, 218–221
mutations of, 182–183
Retinoblastoma (Rb) gene, in islet cell tumors, pancreatic, 110
in parathyroid carcinoma, 104
Revascularization, surgical, for renovascular hypertension, 247–248
RU 486, for Cushing's disease, 314

Salt sensitivity, and obesity-associated hypertension, 407
Salt wasting, from 11β-hydroxylase deficiency, 330–331
Scrotum, examination of, 703–704
Semen, abnormal, descriptors of, 729
analysis of, historical perspective, 725–726
in male infertility, 784–785
profile in, 726–729. See also *Semen profile.*
toxin effects on, 790
Semen profile, abnormal values in, 729
cellular elements in, 727
motility in, 726–727
normal values in, 727–728
prognostic significance of, 729
quality control in, 728–729
sample collection and delivery in, 726
sperm concentration in, 727
spermatozoa in, morphology of, 727
Seminal fluid analysis and sperm function testing, **725–748.** See also *Semen, analysis of; Sperm.*
Seminiferous tubule, failure of, infertility from, 785–786
Sertoli cell only (Del Castillo's) syndrome, 755
Sex hormone-binding globulin (SHBG), in testicular function, 711–712
Sexual function, in aging men, androgen and, 882
SHBG (sex hormone-binding globulin), in testicular function, 711–712
Sickle cell disease, hypogonadism from, male, 766
Skin, in Cushing's syndrome, acanthosis nigricans in, 494–495
facial, 492–493
in dogs and cats, 679–681
striae in, 493
wound healing in, 495
Sodium balance, in renovascular disease, 238–240
Somatostatinoma, in MEN 1, 59
Sperm, analysis of, clinical value of, 732
computer-aided, 729–730
mechanisms of, 730–732
autoimmunity of, in infertility, 787–788
toxin effects on, 790
Sperm function test(s), acrosome reaction, 736–739
biochemistry in, 740–742
sperm-cervical mucus interaction, 732–734
sperm-egg interaction, 733, 735
sperm-oocyte fusion, 739–740
sperm-zona interaction, 735–736
Spermatogenesis, 839–840
endocrine control of, 896
initiation and maintenance of, gonadotropin therapy for, 869–871
process of, 895–896
Sperm-cervical mucus interaction test, of sperm function, 732–734
Sperm-egg interaction test, of sperm function, 733, 735
Sperm-oocyte fusion test, of sperm function, 739–740
Sperm-zona interaction test, of sperm function, 735–736
Spinal cord damage, temporal lobe, 847
Spironolactone, for 11β-hydroxylase deficiency, 334
for 17α-hydroxylase deficiency, 353
for primary aldosteronism, 279–280
Stem cell theory, for benign prostatic hypertrophy, 798
Stenosis, renal artery, and renovascular hypertension, 235–249
Steroidogenesis, 839–840
Steroids, combination, for male contraception, 899–901
ethnic differences and, 901
11β-hydroxylase deficiency, and related disorders, **325–339**
biochemical abnormalities, 329–330
biochemistry of adrenal steroid biosynthesis, 326–328
clinical presentation, 330–332
genetic basis, 332–333
treatment, 333–336
17α-hydroxylase deficiency, clinical manifestations of, 345
deoxycorticosterone activity in, 349–350
deoxycorticosterone and mineralocorticoid hypertension in, 350–351
disorders of, **341–357**
familial studies of, 354
hyperaldosteronism in 17α-hydroxylase/17,20-lyase deficiency, 351–353
pathophysiology of, 345, 347–348
prevalence of, 344
treatment of, 353–354
in aldosteronism, glucocorticoid-remediable, 288–290

Stromal-epithelial interaction theories, for benign prostatic hypertrophy, 798
Strongyloides, risk for, glucocorticoids and, 662
Sympatholytic drugs, erectile dysfunction from, 777

Testis(es), dysfunction of, in autoimmune disease, 848–849
in gastrointestinal disease, 847
in hemoglobinopathies, 847–848
in hypercortisolism, 848
in immune disease, 848–849
in neurologic disorders, acquired, 846–847
in systemic disease, **839–856**
clinical evaluation of, 840–841
hepatic, 843–844
malignant, 845
mechanisms of, 841–842
renal, 842–843
respiratory, 844–845
testicular physiology and, 839
in thyroid disease, 848
medications associated with, 701
risk factors for, 700
examination of, 703–704
function of, androgens in, 5α-reduced, 716–717
estrogens in, 716–717
gonadotropin subunits in, 714–715
gonadotropins in, 712–714
bioassays and radioreceptors assays for, 715
inhibin in, 717–718
prolactin in, 716
sex hormone-binding globulin in, 711–712
testosterone in, 709–711
tests of, GnRH, 718–720
response to antiestrogens, 718
response to human chorionic gonadotropin, 718
in hypogonadism, failure of, autoimmune, 760
feminization of, 758
irradiation of, 760
leprosy and, 759–760
LH-resistant, in hypogonadism, 757
physiology of, 859–860
trauma to, 760
measurement of, 705
Testosterone, for contraception, trials of, 897–899
for hypogonadism, implants, 865–866
new preparations of, 866
transdermal, 864–865
in combination contraceptives, testosterone cypionate-depot medroxyprogesterone acetate, 900
testosterone enanthate-depot medroxyprogesterone acetate, 899–900
testosterone-levonorgestrel, 900
in testicular function, 709–711
levels of, in older men, 877–878
production of, enzymatic defects in, 755–756
replacement of, forms of, 886
serum, in obesity, 767
sex hormone-binding globulin effect on, free or bioavailable, 712
Thiazolidinediones, for hypertension, obesity-associated, 419–420
Thromboembolism, in Cushing's syndrome, in adults, 499
in dogs and cats, 683
Thyroid axis, and hypothalamic-pituitary-adrenal axis, 457
Thyroid gland, carcinoma of. See *Medullary thyroid carcinoma (MTC).*
disorders of, erectile dysfunction in, 381–384
hypertension in, **379–386**
hyperthyroidism, 382–384
hypothyroidism, 379–382
testicular dysfunction in, 848
Thyroidectomy, for MEN 2 syndromes, 162–164, 224–225
prophylactic, for MEN 2A and MEN 2B, 225
Thyroxine replacement therapy, for hypothyroidism and hypertension, 380–381
TNM (tumor-node-metastasis) staging system, for prostate cancer, 811–812
Toxoplasmosis, risk for, glucocorticoids and, 662
Transurethral ultrasonography, in prostate cancer diagnosis, 815
Trauma, cranial, hypogonadotropic hypogonadism from, 764
hypogonadism from, cranial, 765
testicular, 760
Tumor suppressor genes, definition of, 95, 190
identification and localization of, 190
in pancreatic islet cell tumors, 111–113
retinoblastoma, 110
in parathyroid carcinoma, retinoblastoma, 104
in parathyroid neoplasia, on chromosome 11, 99–103
in tumorigenesis, 119
Tumor-node-metastasis (TNM) staging system, for prostate cancer, 811–812

Ultrasonography, duplex, for diagnosis of renovascular hypertension, 245–246

Vacuum constriction device (VCD), for erectile dysfunction, 778–780
Vaginoplasty, for congenital adrenal hyperplasia, 335
Vanillylmandelic acid, in diagnosing pheochromocytoma, 395
Varicella zoster infection, risk for, glucocorticoids and, 663
Vasoactive intestinal peptide (VIP), secretion of, islet cell tumors, 59
VCD. See *Vacuum constriction device (VCD).*
VIP. See *Vasoactive intestinal peptide (VIP).*
VIPoma (vasoactive intestinal peptide-secreting adenoma), in MEN 1, 59
Virilization, from 11β-hydroxylase deficiency, 331–332
  physical examination for, 702–703
Vitamin D, for osteoporosis, 648–649
von Hippel-Lindau disease, pheochromocytoma with, 392–393

Weight loss, for hypertension, obesity-associated, 417
Wermer's syndrome. See *Multiple endocrine neoplasia (MEN), type 1.*
Wilms' tumor, renin hypersecretion from, 263

XYY syndrome, male, 754

Zona-free oocyte penetration test, of sperm function, 739–740